Ceralasertib is an oral ATR inhibitor that has demonstrated in vivo synergy with cisplatin against NSCLC.25 When ATM-deficient NSCLC cell lines were treated with ceralasertib, synthetic lethality was observed. Here, ATR is linked to non-small cell lung carcinoma.